Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38 results about "Reabsorption" patented technology

In renal physiology, reabsorption or tubular reabsorption is the process by which the nephron removes water and solutes from the tubular fluid (pre-urine) and returns them to the circulating blood. It is called reabsorption (and not absorption) both because these substances have already been absorbed once (particularly in the intestines) and because the body is reclaiming them from a postglomerular fluid stream that is well on its way to becoming urine (that is, they will soon be lost to the urine unless they are reclaimed). Substances are reabsorbed from the tubule into the peritubular capillaries. This happens as a result of sodium transport from the lumen into the blood by the Na⁺/K⁺ATPase in the basolateral membrane of the epithelial cells. Thus, the glomerular filtrate becomes more concentrated, which is one of the steps in forming urine. Reabsorption allows many useful solutes (primarily glucose and amino acids), salts and water that have passed through Bowman's capsule, to return to the circulation. These solutes are reabsorbed isotonically, in that the osmotic potential of the fluid leaving the proximal convoluted tubule is the same as that of the initial glomerular filtrate. However, glucose, amino acids, inorganic phosphate, and some other solutes are reabsorbed via secondary active transport through cotransport channels driven by the sodium gradient.

Tetrapeptide LILP with uric acid reducing activity and application thereof

The invention discloses a tetrapeptide LILP with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tetrapeptide LILP is Leuu-Ile-Leu-Pro, and the amino acid sequence of the tetrapeptide LILP is shown in the specification. The invention discloses that the tetrapeptide LILP has uric acid reducing activity for the first time, and uric acid generation can be reduced by reducing the activity of xanthine oxidase in the liver; uric acid discharge can be increased by reducing kidney uric acid reabsorption. The invention provides a multi-target active substance for reducing uric acid, which can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of health-care foods for assisting in reducing the level of uric acid, and has a good application prospect.
Owner:HANGZHOU KANGYUAN FOOD SCI & TECH +1

Tripeptide LAF with uric acid reducing activity and application thereof

The invention discloses a tripeptide LAF with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tripeptide LAF is Leu-Ala-Phe (Leu-Ala-Phe). The tripeptide LAF disclosed by the invention has uric acid reducing activity for the first time, and the generation of uric acid can be reduced by reducing the activity of xanthine oxidase in the liver; meanwhile, uric acid discharge is increased by reducing kidney uric acid reabsorption. The invention provides an active substance for reducing uric acid through multi-target action, and the active substance can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of foods for assisting in reducing the uric acid level, and has a good application prospect.
Owner:HANGZHOU KANGYUAN FOOD SCI & TECH +1

Lactobacillus brevis strain and application of lactobacillus brevis strain in preparation of medicine for preventing or treating hyperuricemia

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.
Owner:ICDC CHINA CDC

Tripeptide LFP with uric acid reducing activity and application thereof

The invention discloses a tripeptide LFP with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tripeptide LFP is Leu-Phe-Pro. The tripeptide LFP disclosed by the invention has uric acid reducing activity for the first time, and the generation of uric acid can be reduced by reducing the activity of xanthine oxidase in the liver; meanwhile, uric acid discharge is increased by reducing kidney uric acid reabsorption. The invention provides a multi-target active substance for reducing uric acid, which can be applied to preparation of drugs for reducing uric acid or foods for assisting in reducing the level of uric acid, and has a good application prospect.
Owner:HANGZHOU KANGYUAN FOOD SCI & TECH +1

Application of product of targeted Vasorin protein in preparation of product for diagnosing or treating kidney diseases with reduced glucose tolerance

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.
Owner:ZHU XIANYI MEMORIAL HOSPITAL OF TIANJIN MEDICAL UNIV (TIANJIN MEDICAL UNIV METABOLIC DISEASE HOSPITAL TIANJIN METABOLIC DISEASE PREVENTION CENT)

Composition for treating hypothyroidism

The present invention discloses a composition for treating hypothyroidism. The formula includes: placenta, antler, Pseudostellaria baicalensis, Salvia miltiorrhiza, and Herba Lycopodii. The prescription of the present invention is demonstrated to have therapeutic effects on hypothyroidism from both traditional Chinese medicine and modern medicine perspectives: from the perspective of traditional Chinese medicine, the efficacy of the present invention in replenishing qi and blood, regulating yin and yang, tonifying kidney essence, filling the marrow sea, and unblocking meridians is unique in treating goiter. From the perspective of modern medicine: Panlushending Jiawei Decoction has the effects of promoting cell reproduction, differentiation, and repairing damaged cells, and is also anti-apoptotic. It also has the effects of promoting the regeneration of vascular endothelial cells, forming new blood vessels, increasing blood flow rate, increasing blood supply, and increasing the secretion and synthesis of thyroid hormones. It can also increase the level of free hormone reabsorption from the intestine and lower the concentration of antibodies.
Owner:AFFILIATED HOSPITAL OF YULIN HEALTH SCHOOL

Traditional Chinese medicine composition for treating hyperuricemia and application thereof

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The preparation method of the traditional Chinese medicine composition comprises the following steps: mixing ganoderma lucidum spore powder and idesia polycarpa fruit powder according to a mass part ratio of (10-90): (90-10), extracting by using a supercritical CO2 fluid extraction technology to obtain an extract phase, then carrying out decompression analysis to precipitate an extract, and drying to obtain traditional Chinese medicine composition powder. The invention provides the traditional Chinese medicine composition compounded by the ganoderma lucidum spore oil and the idesia oil, and cell experiments and animal experiments prove that the traditional Chinese medicine composition can remarkably inhibit uric acid synthesis and reabsorption, so that the level of serum uric acid is reduced, renal function impairment caused by hyperuricemia is improved, and the curative effect is improved. The compound can be used as a functional raw material for preparing a product for treating hyperuricemia or improving kidney injury caused by hyperuricemia; the raw materials are easy to obtain, the cost is low, the safety is high, and good development and application values are achieved.
Owner:ZHEJIANG FORESTRY UNIVERSITY

Kidney unit function demonstration model

ActiveCN223362743UEducational modelsNephronAnatomy
The utility model relates to the technical field of teaching models, and discloses a renal unit function demonstration model, which comprises a glomerulus model, a renal capsule model and a renal tubule model, the lower end of the glomerulus model is connected with the renal capsule model, and the lower end of the renal capsule model is connected with the renal tubule model; according to the utility model, the structure and the function of the kidney unit are visually displayed through the three-dimensional model, the teaching effect is improved, and the defects that the graphic planarity in a teaching material is relatively abstract, only can be displayed statically, is lack of stereoscopicity and intuitiveness, and cannot dynamically simulate the formation process of urine are overcome; by simulating the movement tracks of blood cells, glucose and urea in the urine forming process, the filter of glomerulus and the reabsorption effect of renal tubules in the urine forming process are visually reflected, and the teaching difficulty is broken through.
Owner:汕尾市教师发展中心

Combined application of scopolamine and hyoscyamine

The present invention discloses the combined use of scopolamine and hyoscyamine in the preparation of a drug for preventing or / and treating hyperuricemia. The combined use has an excellent synergistic effect, can significantly reduce the levels of serum uric acid, creatinine, and urea nitrogen, reduce the reabsorption of uric acid, creatinine, and urea nitrogen in urine by the kidney, and promote the excretion of the three, has significant anti-hyperuricemia activity, and has a protective effect on the kidney; it can also significantly reduce the generation of inflammatory factors, effectively improve the symptoms of joint swelling in gouty arthritis, and has clinical application value and development prospects.
Owner:CHINA PHARM UNIV

Kidney organoid culture and multifunctional detection integrated micro-fluidic chip

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

CD70-specific nanoantibodies, molecular imaging probes, and preparation methods and applications thereof

The present invention provides a CD70-specific nanoantibody, a molecular imaging probe, and a preparation method and application thereof. The probe includes a tumor-targeting group, a radionuclide, and a bifunctional chelator; the tumor-targeting group is a CD70-specific nanoantibody; the CD70-specific nanoantibody is RD06, and the amino acid sequence of RD06 is shown in SEQ ID No. 1. The probe of the present invention can achieve non-invasive diagnosis of solid tumors such as renal clear cell carcinoma and hematological malignancies; and through charge adjustment, it effectively inhibits its reabsorption in the kidney, significantly reduces renal uptake, reduces nonspecific signals, improves the signal-to-noise ratio during targeted imaging or treatment, and improves imaging quality and treatment safety. This probe not only has broad application prospects in tumor diagnosis, but also provides new technical support for targeted therapy and personalized precision medicine, and has important scientific research and clinical application value.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Renal disease evaluation assistance method, renal disease evaluation system, and renal disease evaluation program

To provide renal disease markers for accurately evaluating and determining a wide range of renal diseases in subjects.SOLUTION: A method of assisting in evaluation of renal disease is provided, the method involving the use of a ratio of reabsorption and excretion of D-serine and / or D-asparagine in the kidney of a subject as an indicator.SELECTED DRAWING: None
Owner:KAGAMI INC

Use of an article targeting vasorin protein in the manufacture of a product for the diagnosis or treatment of impaired glucose tolerance nephropathy

The application provides application of a preparation targeting a Vasorin protein in preparation of a diagnosis or treatment product for impaired glucose tolerance kidney disease, and belongs to the technical field of biological medicine. Vasorin is used as a biomarker for impaired glucose tolerance kidney disease, and absolute quantification of the level of Vasorin in urine of patients through ELISA technology has great clinical value and practical significance for early discovery and intervention of impaired glucose tolerance kidney disease. Taking a gene controlling expression of Vasorin or the Vasorin protein as a target, overexpression of the gene or the protein by using a specific carrier can effectively improve lipid droplet deposition in renal tubular epithelial cells, excessive generation of reactive oxygen species (ROS), and the ability of the renal tubular epithelial cells to reabsorb albumin, so that effective treatment of impaired glucose tolerance kidney disease is achieved.
Owner:ZHU XIANYI MEMORIAL HOSPITAL OF TIANJIN MEDICAL UNIV (TIANJIN MEDICAL UNIV METABOLIC DISEASE HOSPITAL TIANJIN METABOLIC DISEASE PREVENTION CENT)

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

It is an object of the present invention to provide a combination of a functional assessment of renal function together with biomarker results in order to improve assessment of patient at risk of, or having, an acute kidney injury. A loop diuretic such as furosemide inhibits luminal active chloride transport throughout the thick ascending limb of Henle, thereby preventing sodium reabsorption and resulting in natriuresis and increased urine flow. Loop diuretic-induced increases in urine output might be a method to assess the integrity of the renal tubular function in the setting of early AKI, and so a kidney's response, or lack thereof, to a diuretic challenge as a clinical assessment of tubular function can identify patients with severe tubular injury before it is clinically apparent (e.g. a rise in creatinine).
Owner:BIOMERIEUX INC

Lactobacillus fermentum HF17 capable of inhibiting xanthine oxidase activity and application of lactobacillus fermentum HF17

The invention discloses lactobacillus fermentum HF17 capable of inhibiting xanthine oxidase activity and application of the lactobacillus fermentum HF17. The lactobacillus fermentum HF17 is lactobacillus fermentum and is preserved in the China Center for Type Culture Collection (CCTCC), and the lactobacillus fermentum HF17 is preserved in the China Center for Type Culture Collection (CCTCC). The preservation number of the strain is CCTCC (China Center For Type Culture Collection) Animal experiments show that the strain has the function of inhibiting the activity of xanthine oxidase to reduce uric acid, and lactobacillus fermentum HF17 reduces gene expression of purine metabolism related enzymes in the liver through mediation to inhibit synthesis of uric acid; according to the present invention, the gene expression of the uric acid secretion transporter in the kidney is up-regulated, the gene expression of the uric acid resorption transporter is down-regulated, and the excretion of uric acid in the mouse body is promoted so as to improve the uric acid level of the hyperuricemia mouse, improve the species richness and diversity of the intestinal flora, and improve the hyperuricemia-related metabolic disorder and other phenomena;
Owner:HARBIN INST OF TECH

Wearable biomechanical artificial kidney hemodialysis device

The invention provides a wearable biomechanical artificial kidney hemodialysis device. The wearable biomechanical artificial kidney hemodialysis device comprises a vascular access artery end and a vascular access vein end, the patient blood circulation unit comprises a first dialyzer, and the other ends of the blood outlet pipe and the blood return pipe are connected with the vascular access artery end and the vascular access vein end respectively; the in-vitro active kidney artery and vein ends of the in-vitro active kidney circulation unit are connected with two ports of the second dialyzer respectively to form an in-vitro active kidney blood circulation channel, and an in-vitro active kidney ureter is connected with the waste liquid storage device. The dialysis fluid and the exchange fluid are filtered and purified through the in-vitro kidney and then recycled, toxins are finally discharged out of the body through urine generated after in-vitro kidney filtration and reabsorption, a large amount of dialysis fluid is not needed in the treatment process, a large amount of waste liquid is not generated, the effectiveness and convenience of dialysis are completely met, and the treatment cost is reduced. The patient can be separated from the constraint of a dialysis chamber, a large dialysis machine and a water treatment system; the device is convenient to carry, high in practicability, remarkable in effect and worthy of popularization.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Combined medicine of naltrexone or structural analogue thereof and URAT1 inhibitor and application of combined medicine

PendingCN120324625AOrganic active ingredientsSkeletal disorderURAT1 InhibitorsXanthine
The invention relates to a combined medicine of naltrexone or a structural analogue thereof and a URAT1 inhibitor and application of the combined medicine. The combined medicine can effectively reduce uric acid, treat hyperuricemia and treat renal injury or renal fibrosis. The combined medicine combines different action mechanisms of the two medicines, and can inhibit the activity of xanthine oxidase and reduce reabsorption of renal tubules at the same time, so that uric acid production is reduced, uric acid excretion is increased, and a stronger uric acid reducing effect is expected to be achieved; the damage caused by renal tubule dilatation can be improved, the fibrosis progress is relieved, and then the effect of relieving kidney injury is achieved.
Owner:CHINA PHARM UNIV

Dipeptide with URAT1 inhibitory activity and application of dipeptide in hyperuricemia medicine

ActiveCN120842303ADipeptide ingredientsSkeletal disorderSerum uric acidDipeptide
The invention discloses a dipeptide with URAT1 inhibitory activity and an application of the dipeptide in a medicine for treating hyperuricemia, particularly an application of the dipeptide in preparation of a medicine for preventing or treating hyperuricemia, and belongs to the technical field of biological medicine. The invention discloses that dipeptides WW (Trp-Trp), HW (His-Trp) and YW (Tyr-Trp) have URAT1 inhibitory activity for the first time, and by targeting URAT1 transporter, reabsorption of uric acid in the kidney is reduced, and discharge of uric acid is increased. Based on HEK-293T cells, the IC50 of the WW, the IC50 of the HW and the IC50 of the YW screened out are 16.68 [mu] mol / L, 3.39 [mu] mol / L and 10.54 [mu] mol / L respectively. Based on a C57BL / 6J male mouse, the three dipeptides screened by the invention have the effect of reducing uric acid, and serum uric acid is respectively reduced by 140.6%, 129.1% and 108.3% 19 days after administration. The invention provides a dipeptide with URAT1 inhibitory activity. The dipeptide can be applied to preparation of a medicine for preventing or treating hyperuricemia or preparation of food for assisting in reducing the uric acid level.
Owner:JIANGNAN UNIV

Method for assisting evaluation of condition of kidneys, system for evaluating condition of kidneys, and program for evaluating condition of kidneys

The present invention provides a method for assisting in the evaluation of the condition of kidneys, a system for evaluating the condition of kidneys, and a program for evaluating the condition of kidneys, using, as an index, the ratio of reabsorption of D-serine and / or D-asparagine in target kidneys and excretion of the D-serine and / or D-asparagine. The present invention also provides a method for monitoring the condition of kidneys and a method for monitoring the effect of treatment on kidney disease.
Owner:KAGAMI INC +1

Spleen-invigorating, dampness-eliminating and turbidity-eliminating formula and application thereof

The invention provides a spleen-invigorating, dampness-eliminating and turbidity-discharging formula and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-60 parts of rhizoma smilacis glabrae, 5-20 parts of pyrrosia lingua, 5-25 parts of yam rhizome, 10-50 parts of lysimachia christinae hance, 5-15 parts of achyranthes bidentata, 10-30 parts of pearl barley, 5-15 parts of endive, 1-10 parts of rhizoma atractylodis, 1-10 parts of golden cypress and 5-25 parts of The spleen-invigorating, dampness-eliminating and turbidity-eliminating prescription can reduce the activity of xanthine oxidase and adenosine deaminase in liver tissues, inhibit the generation of uric acid, regulate the expression of an intestinal and kidney urate transporter, reduce uric acid reabsorption and increase uric acid excretion, plays a role in protecting kidney organs while reducing uric acid, and does not cause damage to the liver structure. The spleen-invigorating, dampness-eliminating and turbidity-eliminating formula has a good application prospect in preparation of medicines for preventing and / or treating hyperuricemia.
Owner:FUJIAN UNIV OF TRADITIONAL CHINESE MEDICINE

Use of crocin I in preparation of drugs for preventing and treating hyperuricemia

The application discloses application of Crocin I in preparation of a medicine for preventing and / or treating hyperuricemia, and the molecular formula of the Crocin I is C44H64O24, and the molecular weight is 976.97. The application regulates the expression of the renal uric acid transporters URAT1, GLUT9, OAT1 and ABCG2 by targeting the expression of the hormone receptors ER and AR of the Crocin I, is beneficial to promoting the excretion of uric acid, and the Crocin I can down-regulate the expression of the uric acid reabsorption related transporters URAT1 and GLUT9, and simultaneously up-regulate the expression of the uric acid excretion related transporters OAT1 and ABCG2, so as to regulate the renal uric acid metabolism from two directions of reducing the uric acid reabsorption and promoting the uric acid excretion, and is beneficial to reducing the blood uric acid level. Therefore, the Crocin I can be used for preparing the medicine for preventing or treating the hyperuricemia and the renal injury induced by the hyperuricemia.
Owner:KUNMING UNIV OF SCI & TECH

Lactococcus lactis SWU-HX39 for relieving hyperuricemia

The present application discloses a lactic acid pediococcus SWU-HX39 with the function of reducing uric acid, and the classification name is lactic acid pediococcus (Pediococcus acidilactici) Pediococcus acidilactici ), which is preserved in the China General Microbiological Culture Collection Center, with the preservation number of CGMCC No.33055, the preservation date of December 13, 2024, and the preservation address of No.3, Xili, Beichen West Road, Chaoyang District, Beijing. The lactic acid pediococcus SWU-HX39 can relieve the kidney damage caused by high uric acid, reduce the synthesis of uric acid, lower the concentration of uric acid in blood, improve the excretion of uric acid in the body, reduce the reabsorption of uric acid in the body, and achieve the effect of reducing uric acid. In addition, SWU-HX39 can reduce the expression of LPS and the expression of inflammatory factors IL-1beta, IL-6 and TNF alpha. That is, it has the functions of anti-inflammation and relieving liver inflammation, and can also increase the content of SCFAs in the body of patients with high uric acid, especially propionic acid, so as to reduce the uric acid level and improve the abnormal uric acid content.
Owner:SOUTHWEST UNIV

Preparation method and application of rhizoma polygonati total flavonoids

The invention belongs to the technical field of extraction and separation, and particularly relates to a preparation method and application of rhizoma polygonati total flavonoids. According to the preparation method provided by the invention, the extraction rate of the total flavonoids of the rhizoma polygonati can be increased, 324 flavonoid components are analyzed and identified in the extracted flavonoid extract and mainly contain flavones, flavanone, flavonol, isoflavone and other flavonoids, the content of effective components is high, the preparation process is simple and controllable, and the method is suitable for large-scale production; the total flavonoids of polygonatum sibiricum provided by the invention can effectively relieve oxidative stress of HK-2 cells induced by uric acid and improve the oxidation resistance of the cells, so that the toxic effect of a hyperuricemia environment on kidney cells is relieved; and further research shows that by adjusting the expression of a kidney uric acid transporter URAT1, uric acid reabsorption can be reduced, kidney uric acid excretion can be promoted, and the compound has a good application prospect in preparation of uric acid lowering drugs, anti-hyperuricemia drugs and the like.
Owner:SHANDONG ACADEMY OF AGRICULTURAL SCIENCES +1

Gallus gallus domesticus beta-lactoglobulin reabsorption-mediated gambogic acid renal delivery system, synthetic method and application thereof

This invention belongs to the field of biomedicine and nanomedicine delivery technology, and relates to a precise renal-targeted delivery system for gambogeylic acid mediated by the β-lactoglobulin reabsorption mechanism, its synthesis method, and applications. The system comprises β-lactoglobulin-PEG-gambogeylic acid nanoparticles, containing β-lactoglobulin as a targeting carrier and gambogeylic acid as the active ingredient, covalently linked by a polyethylene glycol chain. This invention utilizes the suitable molecular size of β-lactoglobulin and its ability to be recognized and reabsorbed by the megalin / cubilin receptor system of renal tubular epithelial cells to construct a nanodelivery system that mimics the physiological process of endogenous protein "filtration-reabsorption." Experiments have shown that this system significantly improves the water solubility and biocompatibility of gambogeylic acid, enabling selective accumulation in the kidneys and efficient capture by renal tubular epithelial cells in vivo. It exhibits superior therapeutic effects in a mouse model of cisplatin- and glycerol-induced acute kidney injury, significantly outperforming the positive control drug NAC.
Owner:JIANGSU UNIV OF SCI & TECH

Composition for prevention, amelioration, or treatment of urination-related diseases comprising cephalotocin

ActiveUS12558397B2Peptide/protein ingredientsUrinary disorderDiseaseVasopressin receptor
The present invention relates to a composition for the prevention, amelioration, or treatment of urination-related disases, comprising cephalotocin. The cephalotocin according to the present invention modulates oxytocin receptors and vasopressin receptors, and has the effect of reducing urine volume by promoting water reabsorption in the kidneys. This means that cephalotocin has a significant antidiuretic effect, and thus, the cephalotocin of the present invention can be variously used in the field of prevention, amelioration, or treatment of urinary disorders or urination-related diseases.
Owner:KOREA RES INST OF CHEM TECH +1

Application of sauropus spatulifolius extract in preparation of product for preventing or treating hyperuricemia

The invention relates to application of sauropus spatulifolius extract in preparation of a product for preventing or treating hyperuricemia. The sauropus spatulifolius extract is obtained by mixing sauropus spatulifolius and a solvent and extracting. The sauropus spatulifolius extract can reduce the serum uric acid level and the uric acid level in urine of a hyperuricemia rat, reduce reabsorption of GLUT9 and URAT1 transporters in kidney tissue and promote secretion of ABCG2 and OAT1 proteins, the uric acid level in the body is adjusted through two ways, and the liver and the kidney are protected; therefore, the sauropus spatulifolius can be applied to the medicine for preventing or treating the hyperuricemia.
Owner:SUZHOU UNIV

Bile acid-paclitaxel micromolecular prodrug, preparation method thereof, and construction method and application of self-assembled nanoparticles of bile acid-paclitaxel micromolecular prodrug

According to the invention, a disulfide bond and carbon-carbon bond bridged bile acid-paclitaxel micromolecule prodrug is designed and synthesized, and a micromolecule prodrug self-assembled nano-drug delivery system is prepared on the basis of the disulfide bond and carbon-carbon bond bridged bile acid-paclitaxel micromolecule prodrug. The preparation method has the advantages that a nano precipitation method is adopted, the prodrug can be self-assembled in water to form the nanoparticles without using a carrier material, the preparation process is simple, and industrialization is easy; the amphiphilic micromolecular prodrug improves the water solubility of paclitaxel (PTX), has high drug loading capacity, and avoids adverse reactions possibly caused by carriers and auxiliary materials; when the nanoparticles are orally administered, bile acid can be used as a targeted switch of an ASBT receptor, and gastrointestinal permeability of the nanoparticles can be enhanced, so that the nanoparticles can be transferred and reabsorbed by ASBT mediation to enter intestinal cells and then enter a circulatory system, and oral bioavailability of PTX is enhanced; the tumor microenvironment reduction sensitivity of the connecting arm enables PTX to be specifically released at a tumor part, so that premature leakage of the medicine is avoided, the curative effect of the medicine is improved, and toxic and side effects are reduced.
Owner:HENAN UNIVERSITY

Application of cinchona element Ia as uric acid reducing medicine

The invention discloses an application of cinchona element Ia as a uric acid lowering drug, and finds that the cinchona element Ia has a remarkable inhibition effect on expression of GLUT9 protein for the first time, and reabsorption of the kidney to uric acid can be effectively reduced by inhibiting expression of the GLUT9 protein, so that excretion of the uric acid from urine is promoted, the serum uric acid level is reduced, and the toxic and side effects of the kidney are reduced. And a new effective way is provided for treatment of hyperuricemia and gout.
Owner:GUIZHOU PROVINCIAL PEOPLES HOSPITAL

Application of forsythin in preparation of medicine for preventing or treating hyperuricemia

The invention provides application of forsythin in preparation of a medicine for preventing or treating hyperuricemia, and belongs to the technical field of medical application. According to the present invention, the research results show that the forsythin can reduce the expression levels of uric acid reabsorption proteins GLUT9 and URAT1, and can increase the expression levels of uric acid secretory proteins ABCG2, OAT1 and OAT3; on the basis, the forsythin can be used as a uric acid excretion accelerant, and is further used for preparing the medicine for preventing or treating hyperuricemia caused by uric acid excretion disorder. In addition, the forsythin can also relieve kidney damage caused by hyperuricemia. The application not only provides a new medical application for forsythin, but also provides a new drug choice for hyperuricemia caused by uric acid excretion disorder, and has important guiding significance for prevention and treatment of hyperuricemia and kidney damage caused by hyperuricemia.
Owner:HUBEI UNIV OF MEDICINE